Selexipag

Selexipag
Clinical data
Trade names	Uptravi
Other names	ACT-293987, NS-304
License data	US DailyMed: Selexipag;
Routes of; administration	By mouth, intravenous
Drug class	prostacyclin receptor agonist
ATC code	B01AC27 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	49%
Protein binding	99%
Metabolism	Activation by carboxylesterases, inactivation by CYP2C8 and others
Metabolites	ACT-333679, the free acid (active metabolite)
Elimination half-life	0.8–2.5 h (selexipag) and 6.2–13.5 h (ACT-333679)
Excretion	93% faeces
Identifiers
	IUPAC name 2-{4-[(5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide;
CAS Number	475086-01-2;
PubChem CID	9913767;
IUPHAR/BPS	7552;
DrugBank	DB11362;
ChemSpider	8089417 ;
UNII	5EXC0E384L;
KEGG	D09994 ;
ChEBI	CHEBI:90844 ;
ChEMBL	ChEMBL238804 ;
CompTox Dashboard (EPA)	DTXSID301027959 ;
ECHA InfoCard	100.237.916
Chemical and physical data
Formula	C26H32N4O4S
Molar mass	496.63 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3;
	InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31); ; Key:QXWZQTURMXZVHJ-UHFFFAOYSA-N;
	(what is this?) (verify)

Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.

The most common side effects include headache, diarrhea, nausea and vomiting, jaw pain, myalgia (muscle pain), pain in the limbs, arthralgia (joint pain) and flushing.

It is available as a generic medication.